843666-40-0

Basic information

• Product Name: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER
• Synonyms: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER;18-(tert-Butoxy)-18-oxooctadecanoic acid;18-(tert-Butoxy)-18-oxostearic acid, tert-Butyl 17-carboxyheptadecanoate;18-(tert-Butoxy);-18-oxooctadecanoic acid;Octadecanedioic acid,1-(1,1-dimethylethyl) ester;18-[(2-methylpropan-2-yl)oxy]-18-oxooctadecanoic acid;Octadecanedioic acid mono(1,1-dimethylethyl) ester
• CAS NO: 843666-40-0
• Molecular Formula: C₂₂H₄₂O₄
• Molecular Weight: 370.58
• Mol File: 843666-40-0.mol

Chemical Properties

• Melting Point: 68 °C
• Boiling Point: 470.7±18.0 °C(Predicted)
• Appearance: /
• Density: 0.950±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER(843666-40-0)
• EPA Substance Registry System: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER(843666-40-0)

Safety Data

• Hazardous Substances Data: 843666-40-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER is used as a chemical intermediate for the synthesis of long-acting, potent exendin-4 based GLP-1 analogs. These analogs are engineered to provide sustained glycemic control, making them valuable for the treatment of diabetes and related metabolic disorders.
Used in Drug Delivery Systems:
OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER is utilized in the development of microstructure-based transdermal delivery systems. These systems offer a non-invasive and patient-friendly approach to administer the engineered GLP-1 analogs, ensuring consistent and controlled drug release for effective glycemic management.

Upstream product

• 871-70-5 octadecanedioic acid 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 45270-18-6 1,18-octadecanedioyl dichloride 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 505-54-4 thapsic acid 
• 821-38-5 1,14-tetradecanedioic acid 
• 41059-02-3 9-bromononanoic acid 

Downstream Products

• 843666-34-2 octadecanedioic acid tert-butyl ester-2,5-dioxopyrrolidin-1-yl ester 
• 1448547-34-9 (S)-1-(aminooxy)-19-carboxy-2,7,16,21-tetraoxo-9,12-dioxa-3,6,15,20-tetraazaoctatriacontan-38-oic acid 

Relevant articles and documents

Preparation method of long-chain alkyl diacid mono-tert-butyl ester

The invention relates to a preparation method of long-chain alkyl diacid mono-tert-butyl ester, belonging to the technical field of organic synthesis. According to the invention, long-chain alkyl diacid is used as an initial raw material and reacts with oxalyl chloride to generate long-chain monoacyl chloride, and the long-chain monoacyl chloride and tert-butyl alcohol are subjected to an esterification reaction to generate the long-chain alkyl diacid mono-tert-butyl ester. According to the invention, a novel synthesis route is adopted, and raw material cost is reduced; and the method has the characteristics of mild reaction conditions, simple process operation, high product purity, high production efficiency and the like, and has good application prospects.

GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE

This disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of using the same, including but not limited to dual agonist peptides of any of SEQ ID NOS. 1-10 or 12-27 conjugated to a non-ionic glycolipid surfactant.

Preparation method of long-chain aliphatic dicarboxylic acid mono-tert-butyl ester

The invention provides a method for obtaining the long-chain aliphatic dicarboxylic acid mono-tert-butyl ester through monohydrolysis of the long-chain aliphatic dicarboxylic acid di-tert-butyl ester by controlling the reaction conditions of monohydrolysis; and the raw material cost is low, the yield is high, the post-treatment method is simple, and the method is suitable for industrial production.

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320

Recently, the first basal oral insulin (OI338) was shown to provide similar treatment outcomes to insulin glargine in a phase 2a clinical trial. Here, we report the engineering of a novel class of basal oral insulin analogues of which OI338, 10, in this publication, was successfully tested in the phase 2a clinical trial. We found that the introduction of two insulin substitutions, A14E and B25H, was needed to provide increased stability toward proteolysis. Ultralong pharmacokinetic profiles were obtained by attaching an albumin-binding side chain derived from octadecanedioic (C18) or icosanedioic acid (C20) to the lysine in position B29. Crucial for obtaining the ultralong PK profile was also a significant reduction of insulin receptor affinity. Oral bioavailability in dogs indicated that C18-based analogues were superior to C20-based analogues. These studies led to the identification of the two clinical candidates OI338 and OI320 (10 and 24, respectively).

Preparation method of octadecanedioic acid mont-butyl - PFP

The invention discloses a preparation method of octadecanedioic acid mont-butyl - PFP, which comprises the preparation of compound 1 and preparation of octadecanedioic acid mont-butyl - PFP. The preparation method of the octadecanedioic acid monoester - PFP comprises the following steps: A1, adding compound 1, pyridine, DMF, opening stirring, completely dissolving, dropwise adding trifluoroacetic acid pentafluorophenol ester, precipitating solid and re-reacting in the reaction kettle. A2. The prepared compound DMF is simple in reaction and post-treatment, is simple in reaction and post-treatment, can be directly used for preparing the octadecanedioic acid mont-butyl 1.4 kg - PFP, and can be directly used for preparing - PFP tert-butyl octadecanedioic acid mont-butyl acid or octadecanedioic acid tert-butyl ester - PFP. 1. The method is simple in reaction and post-processing.

A process for preparing a fatty acid derivative method and its application (by machine translation)

The invention discloses a method for preparing a fatty acid derivative method and its application. The first method is the long-chain fatty acid and thionyl chloride reaction, to obtain the acyl chloride; acyl chloride of preparing butanol reaction, then remove chlorine group, and get long-chain fatty acid uncle ding zhi; then and N - hydroxysuccinimide reaction, long-chain fatty acid succinimide and high yield butylacrylate; then with the L - glutamic acid - 1 - tert-butyl reaction, to obtain tert-butyl long-chain fatty acyl - L - Glu - OtBu; with the N - hydroxysuccinimide reaction, to obtain tert-butyl long-chain fatty acyl - L - Glu (OSu)- OtBu; finally [...] butyl long-chain fatty acyl - L - Glu (OSu)- OtBu tert-butyl in removing, and get long-chain fatty acid derivatives. The method routes the operation is simple, quality is controllable, is suitable for industrial production, and low cost, simple purification at the same time, suitable for use in the preparation of high purity insulin analogs. (by machine translation)

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Method for producing long-chain diacid monoester

The invention provides a method for producing long-chain diacid monoester. The method comprises the following steps: carrying out reaction on diacid and benzyl alcohol or tert-butyl alcohol in tolueneunder the condition that an acidic catalyst exists; cooling a reaction solution until the residual diacid is precipitated; filtering diacid sediment; furthermore, cooling the reaction solution untilmonoester is precipitated; filtering sediment of the monoester shown as a formula I. The method provided by the invention can be used for harvesting monoester with high yield and undesired byproductsare reduced to be zero.

MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.